Financial Performance - The company's operating revenue for Q1 2025 was CNY 478,277,626.29, representing a year-on-year increase of 29.79% compared to CNY 368,493,182.74 in the same period last year[4]. - Net profit attributable to shareholders was CNY 108,328,394.49, up 25.20% from CNY 86,524,846.42 in the previous year[4]. - Basic earnings per share increased to CNY 0.60, reflecting a growth of 25.00% from CNY 0.48 in the same period last year[4]. - The company reported a net profit margin of approximately 25.2% for Q1 2025, compared to 27.7% in Q1 2024, indicating a slight decrease in profitability[18]. - The net profit for the first quarter of 2025 was CNY 112,679,007.56, representing an increase of 25.5% compared to CNY 89,830,881.46 in the same period of 2024[19]. - The total comprehensive income for the first quarter of 2025 was CNY 114,707,702.64, compared to CNY 88,482,397.47 in the same quarter of 2024, reflecting a growth of 29.6%[20]. Research and Development - The total R&D investment reached CNY 31,011,792.62, an increase of 30.59% compared to CNY 23,747,449.99 in the same period last year[5]. - The proportion of R&D investment to operating revenue was 6.48%, slightly up from 6.44% in the previous year, indicating a stable commitment to innovation[5]. - Research and development expenses increased to CNY 31,011,792.62 in Q1 2025 from CNY 23,747,449.99 in Q1 2024, representing a growth of 30.5%[19]. Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 78.25%, amounting to CNY 7,838,608.56, down from CNY 36,040,696.10 in the previous year[4][8]. - The company reported a net cash flow from operating activities of CNY 7,838,608.56 for Q1 2025, a decrease from CNY 36,040,696.10 in Q1 2024[22]. - The company experienced a net cash outflow from financing activities of CNY 99,974,321.37 in Q1 2025, compared to a net outflow of CNY 36,855,729.98 in Q1 2024[23]. - Cash and cash equivalents as of March 31, 2025, amounted to RMB 1,155,884,364.75, a decrease of 5.1% from RMB 1,218,066,541.84 at the end of 2024[14]. - The cash and cash equivalents at the end of Q1 2025 were CNY 874,377,121.63, compared to CNY 829,604,106.71 at the end of Q1 2024[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,183,596,590.91, a decrease of 2.91% from CNY 4,309,115,661.76 at the end of the previous year[5]. - Total assets decreased to RMB 4,183,596,590.91 as of March 31, 2025, down from RMB 4,309,115,661.76 at the end of 2024, a decline of 2.9%[16]. - Total liabilities as of March 31, 2025, were RMB 822,381,968.11, down from RMB 1,073,922,464.22 at the end of 2024, a reduction of 23.4%[16]. - The company's equity attributable to shareholders increased to RMB 3,268,454,713.94 as of March 31, 2025, compared to RMB 3,146,979,859.56 at the end of 2024, an increase of 3.9%[16]. - Long-term investments rose to RMB 170,043,207.76 as of March 31, 2025, compared to RMB 153,525,422.38 at the end of 2024, reflecting an increase of 10.7%[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were RMB 357,938,320.14, up 34.4% from RMB 266,229,073.98 in Q1 2024[18]. - Operating income for Q1 2025 was RMB 120,339,306.15, reflecting a growth of 20.5% compared to RMB 102,264,108.76 in Q1 2024[18]. - The total operating expenses for Q1 2025 were CNY 31,373,751.23 in sales expenses, up from CNY 24,771,337.72 in Q1 2024, marking a rise of 26.5%[19].
宏华数科(688789) - 2025 Q1 - 季度财报